4//SEC Filing
Piekos Brian 4
Accession 0001815308-25-000004
CIK 0001348911other
Filed
Nov 25, 7:00 PM ET
Accepted
Nov 26, 6:50 PM ET
Size
9.4 KB
Accession
0001815308-25-000004
Insider Transaction Report
Form 4
Piekos Brian
Chief Financial Officer
Transactions
- Exercise/Conversion
Common Stock
2025-11-21+15,000→ 15,000 total - Sale
Common Stock
2025-11-24$13.45/sh−4,471$60,139→ 10,529 total - Exercise/Conversion
Restricted Stock Unit
2025-11-21−15,000→ 65,000 total→ Common Stock (15,000 underlying)
Footnotes (3)
- [F1]Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.
- [F2]The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
- [F3]3/16th of the total number of shares underlying the RSUs vested on November 21, 2024 and 1/16 shall vest on each quarterly anniversary of the Vesting Commencement Date thereafter, for so long as grantee's Service (as defined in the Plan) does not terminate.
Documents
Issuer
KalVista Pharmaceuticals, Inc.
CIK 0001348911
Entity typeother
Related Parties
1- filerCIK 0001815308
Filing Metadata
- Form type
- 4
- Filed
- Nov 25, 7:00 PM ET
- Accepted
- Nov 26, 6:50 PM ET
- Size
- 9.4 KB